EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

CRISPR-Cas Genome Editing in Ex Vivo Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics

Kumi Mesaki iD, Haruchika Yamamoto, Stephen Juvet, Jonathan Yeung, Zehong Guan, Akhi Akhter, Yan Yao, Cameron Dickie, Henna Mangat, Aizhou Wang, Gavin W Wilson, Andrea Mariscal und 6 weitere

Human Gene Therapy · 2024-06 · 35 (11-12) · 374-387

DOI: 10.1089/hum.2023.223 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Human Gene Therapy, online erschienen am 22.06.2024. Verfasst von Kumi Mesaki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Lung. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The ongoing advancements in CRISPR-Cas technologies can significantly accelerate the preclinical development of both in vivo and ex vivo organ genome-editing therapeutics. One of the promising applications is to genetically modify donor organs prior to implantation. The implantation of optimized donor organs with long-lasting immunomodulatory capacity holds promise for reducing the need for lifelong potent whole-body immunosuppression in recipients. However, assessing genome-targeting interventions in a clinically relevant manner prior to clinical trials remains a major challenge owing to the limited modalities available. This study introduces a novel platform for testing genome editing in human lungs ex vivo , effectively simulating preimplantation genetic engineering of donor organs. We identified gene regulatory elements whose disruption via Cas nucleases led to the upregulation of the immunomodulatory gene interleukin 10 ( IL-10) . We combined this approach with adenoviral vector-mediated IL-10 delivery to create favorable kinetics for early (immediate postimplantation) graft immunomodulation. Using ex vivo organ machine perfusion and precision-cut tissue slice technology, we demonstrated the feasibility of evaluating CRISPR genome editing in human lungs. To overcome the assessment limitations in ex vivo perfused human organs, we conducted an in vivo rodent study and demonstrated both early gene induction and sustained editing of the lung. Collectively, our findings lay the groundwork for a first-in-human-organ study to overcome the current translational barriers of genome-targeting therapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingCRISPR-Cas SystemsLungHumansInterleukin-10AnimalsGenetic Vectors

Stichwörter der Autor:innen

CRISPRIL-10ex vivo perfusiongenome editingprecision-cut tissue slices

Substanzen

Interleukin-10

Autor:innen und Institutionen

  • Latner Thoracic Research Laboratories, Toronto General Hospital Research Institute, University Health Network, Toronto, Canada.
  • Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Division of Respirology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Division of Thoracic Surgery, Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Department of Surgery, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
  • Department of Laboratory Medicine and Pathobiology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.

ORCID-Profile: Kumi Mesaki

Förderung

  • NCI NIH HHS

Zitieren

APA

Mesaki, K., Yamamoto, H., Juvet, S., Yeung, J., Guan, Z., Akhter, A., Yao, Y., Dickie, C., Mangat, H., Wang, A., Wilson, G. W., Mariscal, A., Hu, J., Davidson, A. R., Kleinstiver, B. P., Cypel, M., Liu, M., & Keshavjee, S. (2024). CRISPR-Cas Genome Editing in Ex Vivo Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics. Human Gene Therapy, 35(11-12), 374-387. https://doi.org/10.1089/hum.2023.223

Vancouver

Mesaki K, Yamamoto H, Juvet S, Yeung J, Guan Z, Akhter A, et al. CRISPR-Cas Genome Editing in Ex Vivo Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics. Human Gene Therapy. 2024;35(11-12):374-387. doi:10.1089/hum.2023.223

BibTeX
@article{Mesaki2024,
  author = {Mesaki, Kumi and Yamamoto, Haruchika and Juvet, Stephen and Yeung, Jonathan and Guan, Zehong and Akhter, Akhi and Yao, Yan and Dickie, Cameron and Mangat, Henna and Wang, Aizhou and Wilson, Gavin W and Mariscal, Andrea and Hu, Jim and Davidson, Alan R and Kleinstiver, Benjamin P and Cypel, Marcelo and Liu, Mingyao and Keshavjee, Shaf},
  title = {CRISPR-Cas Genome Editing in Ex Vivo Human Lungs to Rewire the Translational Path of Genome-Targeting Therapeutics},
  journal = {Human Gene Therapy},
  year = {2024},
  volume = {35},
  number = {11-12},
  pages = {374--387},
  doi = {10.1089/hum.2023.223}
}
Kostenlos starten →